Inspire Investing LLC Purchases 528 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Inspire Investing LLC grew its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 10.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,606 shares of the biopharmaceutical company’s stock after buying an additional 528 shares during the period. Inspire Investing LLC’s holdings in Intra-Cellular Therapies were worth $410,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. EFG Asset Management North America Corp. increased its position in Intra-Cellular Therapies by 0.5% during the second quarter. EFG Asset Management North America Corp. now owns 34,452 shares of the biopharmaceutical company’s stock worth $2,357,000 after acquiring an additional 163 shares during the period. Kapitalo Investimentos Ltda acquired a new stake in shares of Intra-Cellular Therapies in the fourth quarter valued at approximately $26,000. Lisanti Capital Growth LLC raised its position in shares of Intra-Cellular Therapies by 0.8% in the first quarter. Lisanti Capital Growth LLC now owns 53,285 shares of the biopharmaceutical company’s stock valued at $3,687,000 after buying an additional 400 shares in the last quarter. Tidal Investments LLC boosted its stake in shares of Intra-Cellular Therapies by 13.9% in the first quarter. Tidal Investments LLC now owns 3,698 shares of the biopharmaceutical company’s stock valued at $256,000 after buying an additional 450 shares during the period. Finally, Headlands Technologies LLC acquired a new stake in Intra-Cellular Therapies during the first quarter worth approximately $32,000. Institutional investors and hedge funds own 92.33% of the company’s stock.

Intra-Cellular Therapies Stock Down 0.4 %

Shares of ITCI stock opened at $78.34 on Friday. The firm has a market capitalization of $8.27 billion, a P/E ratio of -67.53 and a beta of 1.00. Intra-Cellular Therapies, Inc. has a twelve month low of $45.50 and a twelve month high of $84.89. The stock’s fifty day simple moving average is $74.43 and its 200 day simple moving average is $72.45.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.03. Intra-Cellular Therapies had a negative return on equity of 11.48% and a negative net margin of 14.93%. The company had revenue of $161.40 million during the quarter, compared to the consensus estimate of $157.74 million. During the same quarter in the prior year, the firm posted ($0.45) earnings per share. The firm’s revenue was up 45.7% compared to the same quarter last year. As a group, equities research analysts expect that Intra-Cellular Therapies, Inc. will post -0.59 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on ITCI shares. Royal Bank of Canada upped their target price on Intra-Cellular Therapies from $106.00 to $108.00 and gave the company an “outperform” rating in a research report on Friday, October 4th. UBS Group reduced their price objective on shares of Intra-Cellular Therapies from $83.00 to $79.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th. JPMorgan Chase & Co. boosted their target price on shares of Intra-Cellular Therapies from $79.00 to $81.00 and gave the company an “overweight” rating in a research report on Wednesday, August 21st. Morgan Stanley increased their price target on shares of Intra-Cellular Therapies from $92.00 to $95.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Finally, The Goldman Sachs Group lowered their price objective on shares of Intra-Cellular Therapies from $77.00 to $74.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th. Two equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat.com, Intra-Cellular Therapies presently has a consensus rating of “Moderate Buy” and a consensus target price of $96.62.

Insider Activity

In related news, CEO Sharon Mates sold 34,396 shares of the stock in a transaction on Friday, August 30th. The stock was sold at an average price of $72.84, for a total value of $2,505,404.64. Following the completion of the sale, the chief executive officer now directly owns 1,070,329 shares in the company, valued at $77,962,764.36. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, CEO Sharon Mates sold 34,396 shares of Intra-Cellular Therapies stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $72.84, for a total value of $2,505,404.64. Following the transaction, the chief executive officer now directly owns 1,070,329 shares of the company’s stock, valued at $77,962,764.36. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Mark Neumann sold 18,714 shares of the stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $75.08, for a total transaction of $1,405,047.12. Following the sale, the executive vice president now directly owns 29,700 shares of the company’s stock, valued at $2,229,876. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 175,316 shares of company stock valued at $13,037,345. Insiders own 3.40% of the company’s stock.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.